Latest From Biotech Now
The second day of #BIOCEO16 kicked off this morning with a look ahead to PDUFA VI and potential ways to improve the drug development and approval process. Moderated by BIO Executive Vice President of Emerging Companies Cartier Esham, the panelists included: Elizabeth Krutoholow, Analyst, Bloomberg Intelligence Jonathan Leff, Partner, Deerfield Management; Chairman, Deerfield Institute Richard F. Pops, Chairman & Chief Executive Officer, Alkermes The challenges and opportunities presented by the growing amount of available “real Read More >
Samuel Isaly, Managing Partner of OrbiMed Advisors, joined BIO CEO & Investor Conference attendees for a Fireside Chat, moderated by David Gluckman, Co-Head of the Global Healthcare Group at Lazard. The discussion called upon Isaly’s wealth of healthcare and pharmaceutical knowledge spanning nearly 50 years, focusing on the value of innovation. OrbiMed has a simple “secret sauce” to their success, they only employ bright, hardworking, honest and lucky people to manage their funds. As a Read More >
Jim Greenwood, President & CEO, Biotechnology Innovation Organization discusses the organizations new campaign, Time is Precious. Greenwood says, “… if we are going to continue to create new treatments and cures we are going to have to continue to invest and attract investment capital.” Watch the full interview below.
Monday at the BIO CEO & Investor Conference featured a 9:30am panel that offered a comprehensive perspective on what is happening in the world of ophthalmology today. The panel was moderated by Tony Gibney, Managing Director, Leerink Partners. The panelists were: Jeffrey L. Cleland, PhD, Interim Chief Executive Officer, GrayBug Guy Eakins, PhD, Vice President, Scientific Affairs, BrightFocus Foundation Nouhad Husseini, Vice President, Business Development, Regeneron David P. Southwell, President and Chief Executive Officer, Inotek Read More >
New York Senator Chuck Schumer joined attendees at the 2016 BIO CEO & Investor Conference this afternoon for a fireside chat, moderated by BIO Chairman Ron Cohen, to discuss current political and public policy issues facing the country and the biopharmaceutical industry. The Senator expressed optimism that progress can be made on a bipartisan basis in a number of areas that will be conducive to investment in medical innovation and the well-paying jobs that such Read More >